Survival of different cell lines in alginate-agarose microcapsules

Eur J Pharm Sci. 2003 Jan;18(1):23-30. doi: 10.1016/s0928-0987(02)00220-8.

Abstract

Cell microencapsulation has emerged as a promising therapeutic strategy to treat a wide range of diseases. The optimisation of this technology depends on several critical issues such as the careful selection of the cell line, the controlled manufacture of microcapsules and the suitable adaptation of the construct design to the selected cell line. In this work, we studied the behavior of hybridoma cells once enclosed in solid and liquefied core alginate-agarose beads. Results show that hybridoma cells presented a better growing pattern and improved their viability and antibody production within liquefied beads. However, when these beads were evaluated with a compression resistance study, they were found to be mechanically more fragile than solid ones. To address this problem, we entrapped non-autologous cells (BHK fibroblast and C2C12 myoblast) in solid alginate-agarose beads and observed that they showed an improved growing profile and prolonged their viability up to 70 days in comparison to the 15 days seen for the hybridoma cells.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alginates / chemistry
  • Alginates / pharmacology*
  • Animals
  • Antibodies, Monoclonal / biosynthesis
  • Capsules
  • Cell Line
  • Cell Survival / drug effects
  • Compressive Strength
  • Fibroblasts / cytology
  • Fibroblasts / drug effects
  • Glucuronic Acid / chemistry
  • Glucuronic Acid / pharmacology*
  • Hexuronic Acids / chemistry
  • Hexuronic Acids / pharmacology*
  • Hybridomas / cytology*
  • Hybridomas / drug effects
  • Hybridomas / metabolism
  • Mice
  • Myoblasts / cytology
  • Myoblasts / drug effects
  • Sepharose / chemistry
  • Sepharose / pharmacology*

Substances

  • Alginates
  • Antibodies, Monoclonal
  • Capsules
  • Hexuronic Acids
  • Glucuronic Acid
  • Sepharose